2021
DOI: 10.2147/btt.s281618
|View full text |Cite
|
Sign up to set email alerts
|

Antibody Therapies for Large B-Cell Lymphoma

Abstract: Large B-cell lymphomas (LBCLs) constitute a subgroup of aggressive but highly curable lymphoproliferative diseases. Treatment of relapsed/refractory (R/R) patients still represents an unmet clinical need, and novel drugs and combinations are in continuous development. The pan-B cell panel of surface antigens that characterizes LBCL leads to a large umbrella of druggable targets. Monoclonal antibodies (mAbs) express their activity against lymphoma by targeting multiple tumor-specific antigens. This category con… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 109 publications
(138 reference statements)
0
1
0
Order By: Relevance
“…CD20 expression varies greatly among B-cell malignancies, patients with the same malignancy, and even subpopulations within a single patient (Pavlasova and Mraz, 2020). CD20 is expressed by about 40% of precursor B-cell ALL cases (DeAngelo, 2015), and most cases of NHL (Novo et al, 2021) and CLL (Nisticò et al, 2020), which leads to CAR-T cells targeting CD20 as an option for treating these diseases (Marofi et al, 2021). The expression of CD20 in Bcell ALL is linked to a poor prognosis (Thomas et al, 2009).…”
Section: Introductionmentioning
confidence: 99%
“…CD20 expression varies greatly among B-cell malignancies, patients with the same malignancy, and even subpopulations within a single patient (Pavlasova and Mraz, 2020). CD20 is expressed by about 40% of precursor B-cell ALL cases (DeAngelo, 2015), and most cases of NHL (Novo et al, 2021) and CLL (Nisticò et al, 2020), which leads to CAR-T cells targeting CD20 as an option for treating these diseases (Marofi et al, 2021). The expression of CD20 in Bcell ALL is linked to a poor prognosis (Thomas et al, 2009).…”
Section: Introductionmentioning
confidence: 99%